Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00630409 · ClinicalTrials.gov registry record · Phase 2
Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma
A Phase 2 study, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00630409 is a Phase 2 study that has completed, run by University of Pittsburgh. The registered enrollment target is 5 participants.
The verdict
NCT00630409, a Phase 2 study, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to test the hypothesis that the combination of gemcitabine and doxil will have clinical activity in patients with metastatic renal cell carcinoma.
Interventions
- DRUG Gemcitabine
- DRUG Doxil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2004-09 |
| Est. Completion | 2009-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00630409
The ClinicalTrials.gov registry entry for NCT00630409 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Gemcitabine is the first listed.
NCT00630409 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00630409 about?
NCT00630409 is a clinical study titled "Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma". The purpose of this study is to test the hypothesis that the combination of gemcitabine and doxil will have clinical activity in patients with metastatic renal cell carcinoma.
What is the current status of trial NCT00630409?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2004-09. Estimated completion is 2009-09.
What interventions are being tested in trial NCT00630409?
The interventions under investigation include: Gemcitabine (DRUG), Doxil (DRUG).
Who is sponsoring clinical trial NCT00630409?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.